{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:32:18Z","timestamp":1793377938558,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40257-021-00595-7","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T16:03:20Z","timestamp":1616515400000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":250,"title":["Rosacea: New Concepts in Classification and Treatment"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-0182","authenticated-orcid":false,"given":"Esther J.","family":"van Zuuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-8014","authenticated-orcid":false,"given":"Bernd W. M.","family":"Arents","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille M. D.","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofieke","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3952-965X","authenticated-orcid":false,"given":"Zbys","family":"Fedorowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-4530","authenticated-orcid":false,"given":"Jerry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"595_CR1","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMcp1506630","volume":"377","author":"EJ van Zuuren","year":"2017","unstructured":"van Zuuren EJ. Rosacea. N Engl J Med. 2017;377:1754\u201364.","journal-title":"N Engl J Med."},{"key":"595_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bjd.15122","volume":"176","author":"J Tan","year":"2017","unstructured":"Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea Consensus (ROSCO) 2019 panel. Br J Dermatol. 2017;176:431\u20138.","journal-title":"Br J Dermatol."},{"key":"595_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jaad.2017.08.037","volume":"78","author":"RL Gallo","year":"2018","unstructured":"Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148\u201355.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/bjd.18420","volume":"182","author":"M Schaller","year":"2020","unstructured":"Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol. 2020;182:1269\u201376.","journal-title":"Br J Dermatol."},{"key":"595_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","volume":"181","author":"EJ van Zuuren","year":"2019","unstructured":"van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65\u201379.","journal-title":"Br J Dermatol."},{"issue":"Suppl 1","key":"595_CR6","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.jaad.2013.04.043","volume":"69","author":"J Tan","year":"2013","unstructured":"Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(Suppl 1):S27-35.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/jdv.13556","volume":"30","author":"J Tan","year":"2016","unstructured":"Tan J, Sch\u00f6fer H, Araviiskaia E, et al. Prevalence of rosacea in the general population of Germany and Russia\u2014the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428\u201334.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"595_CR8","first-page":"282","volume":"179","author":"L Gether","year":"2018","unstructured":"Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179:282\u20139.","journal-title":"Br J Dermatol."},{"key":"595_CR9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","volume":"80","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019;80:1722\u20139.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR10","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s13555-019-00322-5","volume":"9","author":"HE Baldwin","year":"2019","unstructured":"Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther (Heidelb). 2019;9:725\u201334.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"595_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jdv.13748","volume":"31","author":"B Halioua","year":"2017","unstructured":"Halioua B, Cribier B, Frey M, Tan J. Feelings of stigmatization in patients with rosacea. J Eur Acad Dermatol Venereol. 2017;31:163\u20138.","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"595_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jaad.2017.09.016","volume":"78","author":"R Haber","year":"2018","unstructured":"Haber R, El Gemayel M. Comorbidities in rosacea: A systematic review and update. J Am Acad Dermatol. 2018;78:786\u201392.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.06.150","volume":"78","author":"RL Gallo","year":"2018","unstructured":"Gallo RL, Granstein RD, Kang S, et al. Rosacea comorbidities and future research: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:167\u201370.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaad.2017.07.055","volume":"78","author":"AD Holmes","year":"2018","unstructured":"Holmes AD, Spoendlin J, Chien AL, et al. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78:156\u201366.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR15","doi-asserted-by":"crossref","unstructured":"Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7:1885.","DOI":"10.12688\/f1000research.16537.1"},{"key":"595_CR16","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","volume":"69","author":"M Steinhoff","year":"2013","unstructured":"Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69:S15-26.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"595_CR17","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/jid.2015.53","volume":"135","author":"ALS Chang","year":"2015","unstructured":"Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Investig Dermatol. 2015;135(6):1548\u201355.","journal-title":"J Investig Dermatol."},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2013.08.006","volume":"69","author":"AD Holmes","year":"2013","unstructured":"Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69:1025\u201332.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR19","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/jid.2010.351","volume":"131","author":"K Yamasaki","year":"2011","unstructured":"Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Investig Dermatol. 2011;131:688\u201397.","journal-title":"J Investig Dermatol."},{"issue":"17","key":"595_CR20","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.3390\/ijms17091562","volume":"15","author":"YR Woo","year":"2016","unstructured":"Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci. 2016;15(17):1562.","journal-title":"Int J Mol Sci."},{"key":"595_CR21","doi-asserted-by":"publisher","first-page":"e105238","DOI":"10.1371\/journal.pone.0105238","volume":"9","author":"HL Kelh\u00e4l\u00e4","year":"2014","unstructured":"Kelh\u00e4l\u00e4 HL, Palatsi R, Fyhrquist N, et al. IL-17\/Th17 pathway is activated in acne lesions. PLoS ONE. 2014;9:e105238.","journal-title":"PLoS ONE"},{"key":"595_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","volume":"15","author":"VD Schwab","year":"2011","unstructured":"Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53\u201362.","journal-title":"J Investig Dermatol Symp Proc."},{"key":"595_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584\u20137.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/bjd.14819","volume":"176","author":"J Tan","year":"2017","unstructured":"Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification. Br J Dermatol. 2017;176:197\u20139.","journal-title":"Br J Dermatol."},{"key":"595_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjd.15173","volume":"176","author":"M Schaller","year":"2017","unstructured":"Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176:465\u201371.","journal-title":"Br J Dermatol."},{"key":"595_CR26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","volume":"82","author":"D Thiboutot","year":"2020","unstructured":"Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82:1501\u201310.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR27","first-page":"641","volume":"6","author":"JF Fowler Jr","year":"2007","unstructured":"Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641\u20135.","journal-title":"J Drugs Dermatol."},{"key":"595_CR28","doi-asserted-by":"crossref","unstructured":"Sanchez J, Somolinos AL, Almod\u00f3var PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53:791\u20137.","DOI":"10.1016\/j.jaad.2005.04.069"},{"key":"595_CR29","unstructured":"Gold LS, Papp K, Lynde, et al. Treatment of rosacea with concomitant use of topical ivermectin 1% Cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study. J Drugs Dermatol. 2017;16:909\u201316."},{"key":"595_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaad.2019.05.063","volume":"82","author":"M Schaller","year":"2020","unstructured":"Schaller M, Kem\u00e9ny L, Havlickova B, et al. A randomized phase 3b\/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82:336\u201343.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337\u201352.","journal-title":"Br J Pharmacol."},{"key":"595_CR32","doi-asserted-by":"crossref","unstructured":"van der Linden MMD, van Ratingen AR, van Rappar DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176:1465\u201374.","DOI":"10.1111\/bjd.15155"},{"key":"595_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2165\/11530200-000000000-00000","volume":"11","author":"A Alikhan","year":"2010","unstructured":"Alikhan A, Kurek L, Feldman SR. The role of tetracyclines in rosacea. Am J Clin Dermatol. 2010;11:79\u201387.","journal-title":"Am J Clin Dermatol."},{"key":"595_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1159\/000235550","volume":"22","author":"HC Korting","year":"2009","unstructured":"Korting HC, Sch\u00f6llmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22:287\u201394.","journal-title":"Skin Pharmacol Physiol."},{"key":"595_CR35","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ajd.12075","volume":"55","author":"LJ Perret","year":"2014","unstructured":"Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014;55:111\u20138.","journal-title":"Australas J Dermatol."},{"key":"595_CR36","first-page":"292","volume":"12","author":"JM Jackson","year":"2013","unstructured":"Jackson JM, Kircik LH, Lorenz J. Efficacy of extended-release 45 mg oral minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in the treatment of rosacea. J Drugs Dermatol. 2013;12:292\u20138.","journal-title":"J Drugs Dermatol."},{"key":"595_CR37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-017-0339-0","volume":"19","author":"U Mrowietz","year":"2018","unstructured":"Mrowietz U, Kedem TH, Keynan R, et al. A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea. Am J Clin Dermatol. 2018;19:427\u201336.","journal-title":"Am J Clin Dermatol."},{"key":"595_CR38","doi-asserted-by":"crossref","unstructured":"Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82:1166\u201373.","DOI":"10.1016\/j.jaad.2020.01.043"},{"key":"595_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjd.18857","volume":"183","author":"G Webster","year":"2020","unstructured":"Webster G, Draelos Z, Graber E, et al. A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea. Br J Dermatol. 2020;183:471\u20139.","journal-title":"Br J Dermatol."},{"key":"595_CR40","unstructured":"Dr Reddy\u2019s Laboratories Limited. A controlled study to assess the efficacy, safety and tolerability of oral DFD-29 extended release capsules. ClinicalTrials.gov. Identifier NCT03340961. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03340961. Accessed 4 Dec 2020."},{"key":"595_CR41","first-page":"685","volume":"13","author":"JJ Leyden","year":"2014","unstructured":"Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13:685\u20138.","journal-title":"J Drugs Dermatol."},{"key":"595_CR42","unstructured":"Sol-Gel Technologies, Ltd. A study of S5G4T-1 in the treatment of papular-pustular rosacea. ClinicalTrials.gov. Identifier NCT03564119https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03564119. Accessed 1 Nov 2020."},{"key":"595_CR43","unstructured":"Sol-Gel Technologies, Ltd. A study of S5G4T-1 in the treatment of papulopustular rosacea. ClinicalTrials.gov. Identifier NCT03448939. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03448939. Accessed 1 Nov 2020."},{"key":"595_CR44","doi-asserted-by":"crossref","unstructured":"Bhatia N, Werschler W, Baldwin H, et al. Efficacy and safety of micro-encapsulated benzoyl peroxide (E-BPO) cream, 5% in papulopustular rosacea: results from two phase 3, vehicle-controlled trials. Presented at Maui Derm for Dermatologists 2020, Maui, Hawaii, January 25\u201329, 2020.","DOI":"10.25251\/skin.5.supp.25"},{"key":"595_CR45","doi-asserted-by":"crossref","unstructured":"Bhatia N, Werschler W, Baldwin H, et al. Long-term efficacy and safety of benzoyl peroxide cream, 5% prepared with micro-encapsulation in papulopustular rosacea: results from an extension of two phase 3, vehicle-controlled trials. Presented at Maui Derm for Dermatologists 2020, Maui, Hawaii, January 25\u201329, 2020.","DOI":"10.25251\/skin.5.supp.25"},{"key":"595_CR46","unstructured":"Sol-Gel Technologies, Ltd. A long term safey study of S5G4T-1 in the treatment of papulopustular rosacea. ClinicalTrials.gov. Identifier NCT03564145. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03564145. Accessed 1 Nov 2020."},{"key":"595_CR47","unstructured":"Park B. FDA to review investigational rosacea treatment epsolay. MPR, September 14, 2020. https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/benzoyl-peroxide-epsolay-for-rosacea-fda-review\/. Accessed 12 Nov 2020."},{"key":"595_CR48","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.19172","volume":"183","author":"AM Kumar","year":"2020","unstructured":"Kumar AM, Chiou AS, Shih YH, et al. An exploratory, open-label, investigator initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. Br J Dermatol. 2020;183:942\u20133.","journal-title":"Br J Dermatol."},{"key":"595_CR49","unstructured":"Messoud Ashina, Danish Headache Center. Efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea (STOP Ros). ClinicalTrials.gov. Identifier NCT04419259. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04419259. Accessed 15 Nov 2020."},{"key":"595_CR50","unstructured":"AOBiome LLC. A study to determine safety and efficacy of b244 in subjects with mild to moderate rosacea. ClinicalTrials.gov. Identifier NCT03590366. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03590366. Accessed 15 Nov 2020."},{"key":"595_CR51","unstructured":"Maruho Co., Ltd. Study to evaluate the long-term safety of a once-daily omiganan topical gel. ClinicalTrials.gov. Identifier NCT02576847. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02576847. Accessed 15 Nov 2020."},{"key":"595_CR52","unstructured":"Maruho Co., Ltd. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. ClinicalTrials.gov. Identifier NCT02576860. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02576860. Accessed15 Nov 2020."},{"key":"595_CR53","unstructured":"Maruho Co., Ltd. A twelve week safety and efficacy study in rosacea. ClinicalTrials.gov. Identifier NCT01784133. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01784133. Accessed 15 Nov 2020."},{"key":"595_CR54","unstructured":"Maruho Co., Ltd. Study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle. ClinicalTrials.gov. Identifier NCT02547441. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02547441. Accessed 15 Nov 2020."},{"key":"595_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cgh.2008.02.054","volume":"6","author":"A Parodi","year":"2008","unstructured":"Parodi A, Paolino S, Greco A, et al. S Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6:759\u201364.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"595_CR56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jaad.2012.11.038","volume":"68","author":"LB Weinstock","year":"2012","unstructured":"Weinstock LB, Steinhoff M. Rosacea and small intestinal bacterial overgrowth: prevalence and response to rifaximin. J Am Acad Dermatol. 2012;68:875\u20136.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR57","unstructured":"Alfasigma S.p.A. Safety and efficacy of rifaximin in patients with papulopustular rosacea and positive lactulose breath test. ClinicalTrials.gov. Identifier NCT03864978. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03864978. Accessed 30 Nov 2020."},{"key":"595_CR58","unstructured":"Dermata Therapeutics. DMT210 topical gel in the treatment of acne rosacea. ClinicalTrials.gov. Identifier NCT03003104. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03003104. Accessed 12 Nov 2020."},{"key":"595_CR59","doi-asserted-by":"publisher","first-page":"106178","DOI":"10.1016\/j.intimp.2019.106178","volume":"79","author":"J Li","year":"2020","unstructured":"Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020;79:106178.","journal-title":"Int Immunopharmacol."},{"key":"595_CR60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jaad.2020.05.050","volume":"84","author":"B Wang","year":"2021","unstructured":"Wang B, Yuan X, Huang X, et al. Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multi-center, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2021;84:543\u20135.","journal-title":"J Am Acad Dermatol."},{"key":"595_CR61","unstructured":"The Royal College of Ophthalmologists. Clinical guidelines\u2014hydroxychloroquine and chloroquine retinopathy: recommendations on monitoring, Jan 2020. Review date December 2020. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2020\/02\/HCR-Recommendations-on-Monitoring.pdf. Accessed 6 Dec 2020."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00595-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T10:35:57Z","timestamp":1623666957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00595-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00595-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"18 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"EJ v Z, MMD vd L, BWMA, SV and ZF: none. JT: advisor, consultant, investigator and\/or speaker and has received honoraria and grants from Almirall, Alfasigma, Bausch Health, Boots-Walgreens, Botanix, Cipher, Galderma, L\u2019Oreal, Promius, Sun.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}